Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
About us Practical matters How to find us R.A. (Rudolf) de Boer
University Medical Center Groningen

R.A. (Rudolf) de Boer

Cardiologist & Head Experimental Cardiology
Profile picture of R.A. (Rudolf) de Boer
Telephone:
+31 50 361 5340 (Laboratory)
+31 50 361 2355 (Clinical Department)
E-mail:
r.a.de.boer umcg.nl

Publications

Associations of Serially Measured NT-proBNP With Incident Heart Failure With Reduced and Preserved Ejection Fraction

Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples

Framingham risk score associates with incident cancer and heart failure

Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study

Relative fat mass as a predictor of incident stroke: evidence from the PREVEND cohort

The Association Between Serially Measured Circulating Biomarker Patterns and Pulmonary Artery Pressures Measured by Invasive Hemodynamic Monitoring

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Age-related penetrance of phospholamban p.Arg14del cardiomyopathy

Albuminuria is associated with increased risk of dementia, independent of eGFR: The SCREAM project

A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) – design and rationale of the left ventricular unloading trial domain

Press/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'